Addendum: Metabolic Syndrome, and Particularly the Hypertriglyceridemic-Waist Phenotype, Increases Breast Cancer Risk, and Adiponectin Is a Potential Mechanism: A Case–Control Study in Chinese Women

In the original article, there were mistakes in Table 6, Table 7, Table 9 as published. The numbers of patients in Table 6 and Table 9 were incorrect. The contents in Table 7 and Table 9 were repetitive to some degree in that we had shown the association between adiponectin with metabolic syndrome and HW phenotype. Therefore, for this Correction, we analyzed the association between adiponectin and metabolic syndrome, and the association in pre- and postmenopausal subgroups in Table 7. In Table 9, we converted the numerical variable into categorical variable, which should provide better guide for clinical practice. In our view, this avoids the repetition. These new tables appear below as Tables 6, 7, 9. The authors apologize for these errors and any confusion that may have arisen due to them and hopes these additional tables sufficiently addresses them.

In the original article, corresponding text of Table 6, Table 7, and Table 9 was corrected.

A correction has been made to Abstract, Results, Paragraph number 1:

In addition, total adiponectin levels among breast cancer patients were much lower than among controls (p = 0.005) only in the HW phenotype subgroup. Furthermore, the HW phenotype was associated with increased risk of estrogen receptor/progesterone receptor-positive (ER+/PR+) breast cancer, with a 95% (OR = 1.95, 95% CI:1.21–3.13) increase. However, there was no significant association between the HW phenotype and both ER+/PR– and ER–/PR– subtypes.

A correction has been made to Results, Cluster Mode of HW Phenotype Significantly Increases Breast Cancer Risk, Paragraph number 3:

HW phenotype was associated with ER+/PR+ breast cancer, with a 95% (OR = 1.95, 95% CI:1.21–3.13) increase in risk for women with a positive HW phenotype. However, there was no significant association between HW phenotype and both ER+/PR– and ER–/PR– subtypes.

A correction has been made to Results, Adiponectin Might Be the Mechanism Linking Metabolic Syndrome to Breast Cancer, Paragraph number 2:

total adiponectin levels among breast cancer patients were much lower than among the controls(p = 0.005) in the HW phenotype subgroup.

A correction has been made to Results, Adiponectin Might Be the Mechanism Linking Metabolic Syndrome to Breast Cancer, Paragraph number 3:

there was a significant difference of total adiponectin in ER+/PR+ (p = 0.028) and ER–/PR– (p = 0.043) breast cancer compared to the controls, who were much lower in the HW phenotype subgroup.

A correction has been made to Discussion, Paragraph number 6:

We revealed that HW phenotype was an independent risk factor for the ER+/PR+ subtype.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Summary

Keywords

breast cancer, metabolic syndrome, hypertriglyceridemic-waist phenotype, adiponectin, risk

Citation

Xiang Y, Zhou W, Duan X, Fan Z, Wang S, Liu S, Liu L, Wang F, Yu L, Zhou F, Huang S, Li L, Zhang Q, Fu Q, Ma Z, Gao D, Cui S, Geng C, Cao X, Yang Z, Wang X, Liang H, Jiang H, Wang H, Li G, Wang Q, Zhang J, Jin F, Tang J, Tian F, Ye C and Yu Z (2020) Addendum: Metabolic Syndrome, and Particularly the Hypertriglyceridemic-Waist Phenotype, Increases Breast Cancer Risk, and Adiponectin Is a Potential Mechanism: A Case–Control Study in Chinese Women. Front. Endocrinol. 11:227. doi: 10.3389/fendo.2020.00227

Received

28 February 2020

Accepted

30 March 2020

Published

04 June 2020

Volume

11 - 2020

Edited and reviewed by

Eva Surmacz, Allysta Pharmaceuticals, Inc., United States

Updates

Check for updates

Copyright

© 2020 Xiang, Zhou, Duan, Fan, Wang, Liu, Liu, Wang, Yu, Zhou, Huang, Li, Zhang, Fu, Ma, Gao, Cui, Geng, Cao, Yang, Wang, Liang, Jiang, Wang, Li, Wang, Zhang, Jin, Tang, Tian, Ye and Yu.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Zhigang Yu yzg@medmail.com.cn

This article was submitted to Translational Endocrinology, a section of the journal Frontiers in Endocrinology

†These authors have contributed equally to this work and share first authorship

Disclaimer

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.